Clinical trial · no report yet · Phase 3
BOND-003
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
- NCT04452591 ↗
- Active not recruiting
- CG Oncology, Inc.
- 57 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 36 | |
| Podcasts | 12 | |
| YouTube | 9 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer
- Interventions
- Cretostimogene Grenadenorepvec; n-dodecyl-B-D-maltoside
- Arms
- Cohort C(All Countries):Enrollment Closed · Experimental
- Cohort P(Japan and United States Only) :Open to Enrollment · Experimental
- Enrollment
- 190 (estimated)
- Primary outcomes
- Cohort C:
- Cohort P:
- Sponsor
- CG Oncology, Inc.
- Start
- Oct 27, 2020
- Primary completion
- Jun 16, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT04452591 · updated Jul 10, 2026
Publications
linked from the registry- Tyson MD 2nd, Nam JK, Joshi SS, Uchio EM, Jung SI, Bivalacqua TJ, Steinberg GD, Shore ND, Burke JM, Kitamura H, Tran B, Li R. Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial. Lancet Oncol. 2026 Aug;27(8):983-993. doi: 10.1016/S1470-2045(26)00194-4. PubMed 42508433